Do you want to read an article? Please log in or register.
Drug Retention Rate and Causes of Discontinuation of Adalimumab in Uveitis: Real-World Data from the Biotherapies in Uveitis (BioÚvea) Study Group
Uveitis
RECOMMENDED
Related content
Macular Diseases
Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti-VEGF Drug Type for 1 Year in the IRIS Registry
Ophthalmology.
Rao P, Lum F, Wood K, Salman C, Burugapalli B, Hall R, Singh S, Parke DW 2nd2, Williams GA
doi: 10.1016/j.ophtha.2017.10.010.
Retinal Diseases
Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources
BMC Ophthalmol.
Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Finger RP, Sakamoto T, Wong TY, Evuarherhe O, Carter G, Carrasco J
doi: 10.1186/s12886-019-1208-9.
Glaucoma and Ocular PressureUveitis
Evaluating the Impact of Uveitis on Visual Field Progression Using Large Scale Real-World Data
Am J Ophthalmol.
Liu X, Kelly SR, Montesano G, Bryan SR, Barry RJ, Keane PA, Denniston AK, Crabb DP
doi: 10.1016/j.ajo.
Macular Diseases
Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
Adv Ther.
Carrasco J, Pietsch GA, Nicolas MP, Koerber C, Bennison C, Yoon J
doi: 10.1007/s12325-019-01147-6.
COMMENTED
Uveitis
Long-Term Safety and Efficacy of Adalimumab in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
Ophthalmology
Suhler EB, Jaffe GJ, Fortin E, Lim LL, Merrill PT, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Van Calster J, Cimino L, Adan A, Goto H, Kaburaki T, Kramer M, Vitale AT, Kron M, Song AP, Liu J, Pathai S, Douglas KM, Schlaen A, Muccioli C, Van Velthoven MEJ, Zierhut M, Rosenbaum JT
doi: 10.1016/j.ophtha.2020.10.036
Macular DiseasesRetinal DiseasesUveitis
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients
Clin Rheumatol.
Fabiani C, Vitale A, Rigante D, Emmi G, Bitossi A, Lopalco G, Sota J, Guerriero S, Orlando I, Gentileschi S, Iannone F, Frediani B, Galeazzi M, Vannozzi L, Tosi GM, Cantarini L
doi: 10.1007/s10067-018-4228-6.
Uveitis
Changing biological disease modifying treatment for paediatric uveitis in the real world
Clin Exp Ophthalmol.
Oh LJ, Nguyen CL, Phan K, Wong E, Zagora S, Singh-Grewal D, Chaitow J, Grigg JR, McCluskey P
doi: 10.1111/ceo.13494.
Uveitis
Efficacy and Safety of Intravitreal Sirolimus for Noninfectious Uveitis of the Posterior Segment: Results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Program
Ophthalmology.
Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, Ohno S, Rathinam SR, Ali Y, Mudumba S, Shams N, Nguyen QD, Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) Study Group.
doi: 10.1016/j.ophtha.2020.03.033.
Uveitis
Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial
Lancet.
Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP
doi: 10.1016/